

David Cella

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7124341/david-cella-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

509
papers

28,640
citations

78
h-index

161
g-index

547
ext. papers

34,972
ext. citations

4.3
avg, IF

7.08
L-index

#	Paper	IF	Citations
509	Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients.. <i>Supportive Care in Cancer</i> , 2022 , 30, 3613	3.9	0
508	Effects of patient-reported outcome assessment order.. <i>Clinical Trials</i> , 2022 , 17407745211073788	2.2	1
507	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	9
506	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102006	2.2	4
505	Do You Recall?: Results From a Within-Person Recall Study of the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v2.0 - Physical Function 8c.. <i>Value in Health</i> , 2022 , 25, 161-166	3.3	0
504	Correlates of financial toxicity in adult cancer patients and their informal caregivers. <i>Supportive Care in Cancer</i> , 2022 , 30, 217-225	3.9	5
503	The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Guidance for Use in Research and Clinical Practice 2022 , 79-104		1
502	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102011	2.2	3
501	The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 83	5.7	0
500	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	6
499	Patient-reported outcomes: what really matters to patients? - Authors' reply.. <i>Lancet Oncology, The</i> , 2022 , 23, e199	21.7	
498	Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre.. <i>BMJ Open</i> , 2022 , 12, e059563	3	0
497	Integration of Palliative and Supportive Care Into the Management of Genitourinary Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 1-10	7.1	0
496	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 52, 151926-151926	5.3	1
495	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. <i>Cancer</i> , 2021 , 127, 4546-4556	6.4	0
494	Quality-of-life methodology in hormone receptor-positive advanced breast cancer: Current tools and perspectives for the future. <i>Cancer Treatment Reviews</i> , 2021 , 102, 102321	14.4	1
493	Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation from International PNH Registry Patient Data. <i>Blood</i> , 2021 , 138, 1952-1952 ^{2,2}		1

492	Symptoms and Impacts Reported By Patients with Acute Myeloid Leukemia (AML) in Remission Post-Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 278-278	2.2	
491	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. <i>Cancer</i> , 2021 ,	6.4	1
490	Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10). <i>Health Science Reports</i> , 2021 , 4, e401	2.2	0
489	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. <i>Neuroendocrinology</i> , 2021 , 111, 850-862	5.6	1
488	Responsiveness and convergent validity of the chronic rhinosinusitis patient-reported outcome (CRS-PRO) measure in CRS patients undergoing endoscopic sinus surgery. <i>International Forum of Allergy and Rhinology</i> , 2021 , 11, 1308-1320	6.3	0
487	Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. <i>Cancer</i> , 2021 , 127, 1360-1368	6.4	2
486	The mediating role of avoidant coping in the relationships between physical, psychological, and social wellbeing and distress in breast cancer survivors. <i>Psycho-Oncology</i> , 2021 , 30, 1129-1136	3.9	0
485	Computerized Adaptive Testing (CAT) and the Future of Measurement-Based Mental Health Care. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2021 , 48, 729-731	3.1	2
484	Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1369-1378	9.7	1
483	Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1239-1242	4.1	3
482	Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of riloncept. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 201	2.3	3
481	Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review. <i>Value in Health</i> , 2021 , 24, 585-591	3.3	8
480	Symptom and needs assessment screening in oncology patients: Alternate outreach methods during COVID-19. <i>Journal of Psychosocial Oncology</i> , 2021 , 39, 452-460	2.8	0
479	PROsetta: An Package for Linking Patient-Reported Outcome Measures. <i>Applied Psychological Measurement</i> , 2021 , 45, 386-388	1.5	1
478	Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results From the FoRtitude Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1495-1505	9.7	3
477	OP0239 PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 146-147	2.4	1
476	Reliability and meaningful change of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire (PIQ) item banks in adults with atopic dermatitis. <i>British Journal of Dermatology</i> , 2021 , 185, 438-439	4	1
475	Association of cognitive impairment and breast cancer survivorship on quality of life in younger breast cancer survivors. <i>Journal of Cancer Survivorship</i> , 2021 , 1	5.1	0

474	International application of PROMIS computerized adaptive tests: US versus country-specific item parameters can be consequential for individual patient scores. <i>Journal of Clinical Epidemiology</i> , 2021 , 134, 1-13	5.7	3
473	Can the Knee Outcome and Osteoarthritis Score (KOOS) Function Subscale Be Linked to the PROMIS Physical Function to Crosswalk Equivalent Scores?. <i>Clinical Orthopaedics and Related Research</i> , 2021 , 479, 2653-2664	2.2	1
472	Linking Scores with Patient-Reported Health Outcome Instruments:A VALIDATION STUDY AND COMPARISON OF THREE LINKING METHODS. <i>Psychometrika</i> , 2021 , 86, 717-746	2.2	3
471	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , 2021 , 24, 862-873	3.3	4
470	Patient-Reported Outcomes in the Phase III BRIGHT E Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals. <i>Patient</i> , 2021 , 1	3.7	1
469	Developing a common metric for depression across adulthood: Linking PROMIS depression with the Edinburgh Postnatal Depression Scale. <i>Psychological Assessment</i> , 2021 , 33, 610-618	5.3	2
468	Comparison of PROMIS Computerized Adaptive Testing versus Fixed Short Forms in Juvenile Myositis. <i>Arthritis Care and Research</i> , 2021 ,	4.7	1
467	Meaning and purpose in Huntington's disease: a longitudinal study of its impact on quality of life. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1668-1679	5.3	3
466	What Is an Important Difference in Gait Speed in Adults With Knee Osteoarthritis?. <i>Arthritis Care and Research</i> , 2021 , 73, 559-565	4.7	5
465	Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials. <i>Arthritis Care and Research</i> , 2021 , 73, 481-488	4.7	0
464	The impact of fear of cancer recurrence on healthcare utilization among long-term breast cancer survivors recruited through ECOG-ACRIN trials. <i>Psycho-Oncology</i> , 2021 , 30, 279-286	3.9	2
463	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	2
462	Characteristics and impacts of itch in children with inflammatory skin disorders. <i>British Journal of Dermatology</i> , 2021 , 184, 896-904	4	1
461	Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 517-523	5.6	0
460	Burden of Recurrent Pericarditis on Health-Related Quality of Life. <i>American Journal of Cardiology</i> , 2021 , 141, 113-119	3	5
459	Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. <i>Advances in Therapy</i> , 2021 , 38, 969-993	4.1	1
458	Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers. <i>JCO Oncology Practice</i> , 2021 , 17, e101-e110	2.3	0
457	Linking Oswestry Disability Index to the PROMIS pain interference CAT with equipercentile methods. <i>Spine Journal</i> , 2021 , 21, 1185-1192	4	0

456	Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques. <i>Journal of Medical Internet Research</i> , 2021 , 23, e24893	7.6	7
455	The PROMIS-Plus-Osteoarthritis of the Knee (OAK) profile measure integrates generic and condition-specific content to enhance relevance and efficiency. <i>Journal of Clinical Epidemiology</i> , 2021 , 135, 158-169	5.7	1
454	Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. <i>Quality of Life Research</i> , 2021 , 30, 2729-2754	3.7	13
453	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 ,	13.4	2
452	Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. <i>Value in Health</i> , 2021 , 24, 1715-1719	3.3	1
451	Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. <i>Gynecologic Oncology</i> , 2021 , 163, 392-397	4.9	
450	Turkish validation and reliability of the symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire in patients with lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2021 , 40, 2034-2040	2.3	
449	Common patient-reported outcomes across ICHOM Standard Sets: the potential contribution of PROMIS [®] . <i>BMC Medical Informatics and Decision Making</i> , 2021 , 21, 259	3.6	2
448	Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia. <i>Journal of Geriatric Oncology</i> , 2021 ,	3.6	1
447	Proposed domains for assessing postpartum recovery: a concept elicitation study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021 ,	3.7	1
446	Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	1
445	Oncologists' knowledge and perspectives on the use of biosimilars.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 35-35	2.2	1
444	Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302). <i>Cancer Medicine</i> , 2020 , 9, 8884-8894	4.8	4
443	Association of atopic dermatitis severity with cognitive function in adults. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1349-1359	4.5	15
442	Symptom burden trajectories experienced by patients with brain tumors. <i>Cancer</i> , 2020 , 126, 3341-3351	6.4	
441	Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy. <i>Cancer</i> , 2020 , 126, 3542-3551	6.4	4
440	Evaluation of Domains of Patient-Reported Outcome Measures for Recovery After Childbirth: A Scoping and Systematic Review. <i>JAMA Network Open</i> , 2020 , 3, e205540	10.4	17
439	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. <i>Gynecologic Oncology</i> , 2020 , 158, 194-200	4.9	3

438	Association of itch triggers with atopic dermatitis severity and course in adults. <i>Annals of Allergy, Asthma and Immunology</i> , 2020 , 125, 552-559.e2	3.2	12
437	Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies. <i>Journal of Clinical Epidemiology</i> , 2020 , 127, 9-18	5.7	5
436	Development of a validated short-form of the Childhood Atopic Dermatitis Impact Scale, the CADIS-SF15. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1773-1778	4.6	7
435	Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). <i>Advances in Therapy</i> , 2020 , 37, 1608-1619	4.1	5
434	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II. <i>Gynecologic Oncology</i> , 2020 , 158, 201-207	4.9	3
433	PROMIS-deaf profile measure: cultural adaptation and psychometric validation in American sign language. <i>Journal of Patient-Reported Outcomes</i> , 2020 , 4, 44	2.6	4
432	Applying the COM-B model to patient-reported barriers to medication adherence in pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28216	3	7
431	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020 , 34, 2451-2459	10.7	9
430	Measurement properties of the Patient-Reported Outcomes Information System (PROMIS) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis. <i>British Journal of Dermatology</i> , 2020 , 183, 891-898	4	15
429	Patient-reported Outcome Measures in Emergency Care Research: A Primer for Researchers, Peer Reviewers, and Readers. <i>Academic Emergency Medicine</i> , 2020 , 27, 403-418	3.4	4
428	The increasing value of eHealth in the delivery of patient-centred cancer care. <i>Lancet Oncology</i> , 2020 , 21, e240-e251	21.7	59
427	Psychometric Evaluation of the Patient-Related Nausea and Vomiting Management Barriers Questionnaire. <i>Journal of Pain and Symptom Management</i> , 2020 , 60, 439-448	4.8	1
426	Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial. <i>Blood</i> , 2020 , 136, 25-26	2.2	
425	Improvements in Fatigue Correlate with Changes in Clinical and Hematological Outcomes: Post Hoc Analyses from the Pegasus Study. <i>Blood</i> , 2020 , 136, 4-5	2.2	
424	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020 , 136, 45-46	2.2	
423	Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). <i>Journal of Patient-Reported Outcomes</i> , 2020 , 4, 106	2.6	19
422	A cohort study of quality of life in partners of young breast cancer survivors compared to partners of healthy controls. <i>Journal of Patient-Reported Outcomes</i> , 2020 , 4, 19	2.6	6
421	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. <i>Journal of Cancer Metastasis and Treatment</i> , 2020 , 6,	3.8	2

420	Optimizing Health Information Technologies for Symptom Management in Cancer Patients and Survivors: Usability Evaluation. <i>JMIR Formative Research</i> , 2020 , 4, e18412	2.5	3
419	Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale. <i>World Journal of Gastrointestinal Oncology</i> , 2020 , 12, 205-218	3.4	5
418	A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10. <i>Journal of Urology</i> , 2020 , 203, 164-170	2.5	6
417	Does recall period matter? Comparing PROMIS physical function with no recall, 24-hr recall, and 7-day recall. <i>Quality of Life Research</i> , 2020 , 29, 745-753	3.7	15
416	HDQLIFE and neuro-QoL physical function measures: Responsiveness in persons with huntington's disease. <i>Movement Disorders</i> , 2020 , 35, 326-336	7	5
415	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020 , 126, 1550-1558	6.4	9
414	Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD). <i>Quality of Life Research</i> , 2020 , 29, 1393-1403	3.7	4
413	Responsiveness to Change Over Time: An Examination of the Neuro-QoL Social Function Measures in Persons with Huntington's Disease. <i>Journal of Huntingtons Disease</i> , 2020 , 9, 83-97	1.9	
412	Measurement properties of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire item banks in adults with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1174-1180	4.5	10
411	Development and refinement of FoRtitude: An eHealth intervention to reduce fear of recurrence among breast cancer survivors. <i>Psycho-Oncology</i> , 2020 , 29, 227-231	3.9	5
410	Pragmatic Health Assessment in Early Childhood: The PROMIS [®] of Developmentally Based Measurement for Pediatric Psychology. <i>Journal of Pediatric Psychology</i> , 2020 , 45, 311-318	3.2	17
409	Longitudinal changes in symptom-based female and male LUTS clusters. <i>Neurourology and Urodynamics</i> , 2020 , 39, 393-402	2.3	4
408	National Quality Forum Guidelines for Evaluating the Scientific Acceptability of Risk-adjusted Clinical Outcome Measures: A Report From the National Quality Forum Scientific Methods Panel. <i>Annals of Surgery</i> , 2020 , 271, 1048-1055	7.8	8
407	A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. <i>Medical Decision Making</i> , 2020 , 40, 897-911	2.5	4
406	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3841-3850	2.3	47
405	Meaning and Dignity Therapies for Psychoneurology in Neuropalliative Care: A Vision for the Future. <i>Journal of Palliative Medicine</i> , 2020 , 23, 1155-1156	2.2	6
404	Measurement Properties of 4 Patient-Reported Outcome Measures to Assess Sleep Disturbance in Adults With Atopic Dermatitis. <i>Dermatitis</i> , 2020 , 31, 321-327	2.6	2
403	PROMIS [®] and Neuro-QoL measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 231-238	2.5	2

402	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020 , 126, 4156-4167	6.4	66
401	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS). <i>Patient Preference and Adherence</i> , 2020 , 14, 971-983	2.4	6
400	Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2020 , 39, 2161-2170	2.3	2
399	The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 629-638	4.4	1
398	Patient demographic and psychosocial characteristics associated with 30-day recall of self-reported lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2020 , 39, 1939-1948	2.3	1
397	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. <i>PLoS ONE</i> , 2020 , 15, e0237497	2.7	8
396	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3494-3505	2.2	13
395	Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD). <i>Quality of Life Research</i> , 2020 , 29, 3419-3439	3.7	4
394	Evaluation of responsiveness and estimation of smallest detectable change and minimal important change scores for the Childhood Atopic Dermatitis Impact Scale. <i>British Journal of Dermatology</i> , 2020 , 182, 348-354	4	4
393	Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 955-963	5	8
392	Development, Validation, and Interpretation of the PROMIS Itch Questionnaire: A Patient-Reported Outcome Measure for the Quality of Life Impact of Itch. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 986-994.e6	4.3	15
391	A comparison of computer adaptive tests (CATs) and short forms in terms of accuracy and number of items administered using PROMIS profile. <i>Quality of Life Research</i> , 2020 , 29, 213-221	3.7	25
390	Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ). <i>Patient Preference and Adherence</i> , 2020 , 14, 705-715	2.4	3
389	Assessing meaning & purpose in life: development and validation of an item bank and short forms for the NIH PROMIS. <i>Quality of Life Research</i> , 2020 , 29, 2299-2310	3.7	10
388	Trends and predictors of multidimensional health-related quality of life after living donor kidney transplantation. <i>Quality of Life Research</i> , 2020 , 29, 2355-2374	3.7	4
387	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1875-1886	2.2	23
386	Self-reported physical activity, sitting time, and mental and physical health among older cancer survivors compared with adults without a history of cancer. <i>Cancer</i> , 2020 , 127, 115-123	6.4	0
385	U.K. utility weights for the EORTC QLU-C10D. <i>Health Economics (United Kingdom)</i> , 2019 , 28, 1385-1401	2.4	18

384	Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 5	2.6	4
383	Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 10	2.6	5
382	Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 30	2.6	13
381	Retraction Note to: Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 32	2.6	0
380	Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease. <i>Journal of Huntingtong Disease</i> , 2019 , 8, 467-482	1.9	7
379	Screening Properties of the Diagnostic Criteria for Cancer-Related Fatigue. <i>Oncology Research and Treatment</i> , 2019 , 42, 440-447	2.8	4
378	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2403-2415	59.2	334
377	Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology. <i>Quality of Life Research</i> , 2019 , 28, 1315-1325	3.7	4
376	Meaningful differences and validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data. <i>Cancer</i> , 2019 , 125, 1877-1885	6.4	2
375	PROMIS Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains. <i>Value in Health</i> , 2019 , 22, 537-544	3.3	129
374	Development and Initial Validation of the PROMIS [®] -Plus-HF Profile Measure. <i>Circulation: Heart Failure</i> , 2019 , 12, e005751	7.6	9
373	A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire. <i>Neurourology and Urodynamics</i> , 2019 , 38, 1751-1759	2.3	5
372	Calibration and initial validation of a general self-efficacy item bank and short form for the NIH PROMIS. <i>Quality of Life Research</i> , 2019 , 28, 2513-2523	3.7	21
371	End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End-of-Life Planning. <i>Journal of Neurology</i> , 2019 , 266, 2406-2422	5.5	5
370	Positive Affect and Well-Being in Huntington's Disease Moderates the Association Between Functional Impairment and HRQOL Outcomes. <i>Journal of Huntingtong Disease</i> , 2019 , 8, 221-232	1.9	1
369	The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. <i>Gynecologic Oncology</i> , 2019 , 154, 13-21	4.9	4
368	Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety. <i>Cancer</i> , 2019 , 125, 3249-3258	6.4	5
367	Bifactor analysis confirmation of the factorial structure of the Functional Assessment of Cancer Therapy-General (FACT-G). <i>Psycho-Oncology</i> , 2019 , 28, 1149-1152	3.9	3

366	Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1650-1657	4.5	11
365	Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms. <i>Cancer</i> , 2019 , 125, 2338-2344	6.4	5
364	Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. <i>BMC Cancer</i> , 2019 , 19, 274	4.8	7
363	Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-BL) among advanced urothelial cancer patients. <i>Supportive Care in Cancer</i> , 2019 , 27, 4189-4198	3.9	15
362	Development and validation of the caregiver roles and responsibilities scale in cancer caregivers. <i>Quality of Life Research</i> , 2019 , 28, 1655-1668	3.7	5
361	Breast cancer survivors' preferences for mHealth physical activity interventions: findings from a mixed methods study. <i>Journal of Cancer Survivorship</i> , 2019 , 13, 292-305	5.1	18
360	Inpatient Rehabilitation Quality of Care From the Patient's Perspective: Effect of Data Collection Timing and Patient Characteristics. <i>Archives of Physical Medicine and Rehabilitation</i> , 2019 , 100, 1032-1041	2.8	4
359	Understanding Health-Related Quality of Life in Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury: Establishing the Reliability and Validity of PROMIS Fatigue and Sleep Disturbance Item Banks. <i>Archives of Physical Medicine and Rehabilitation</i> , 2019 , 100, 3102-3109	2.8	20
358	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019 , 15, 1683-1695	3.6	19
357	Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. <i>Quality of Life Research</i> , 2019 , 28, 3355-3362	3.7	19
356	Implementing electronic health record-integrated screening of patient-reported symptoms and supportive care needs in a comprehensive cancer center. <i>Cancer</i> , 2019 , 125, 4059-4068	6.4	21
355	A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 356-365.e13-3	3.3	8
354	Use of PROMIS-29 in US Veterans: Diagnostic Concordance and Domain Comparisons with the General Population. <i>Journal of General Internal Medicine</i> , 2019 , 34, 1452-1458	4	7
353	The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3-Mutated (FLT3mut+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study. <i>Blood</i> , 2019 , 134, 1332-1332	2.2	5
352	The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study. <i>Blood</i> , 2019 , 134, 3850-3850	2.2	5
351	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS684-TPS684	2.2	4
350	Interviewer- versus self-administration of PROMIS measures for adults with traumatic injury. <i>Health Psychology</i> , 2019 , 38, 435-444	5	21
349	PROMIS : Standardizing the patient voice in health psychology research and practice. <i>Health Psychology</i> , 2019 , 38, 343-346	5	10

348	The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms. <i>Journal of Urology</i> , 2019 , 201, 1177-1183	2.5	9
347	Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss. <i>Quality of Life Research</i> , 2019 , 28, 1641-1653	3.7	7
346	Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03). <i>Quality of Life Research</i> , 2019 , 28, 1265-1269	3.7	1
345	PRO-Bookmarking to Estimate Clinical Thresholds for Patient-reported Symptoms and Function. <i>Medical Care</i> , 2019 , 57 Suppl 5 Suppl 1, S13-S17	3.1	19
344	Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials. <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 185	3	3
343	Development of the Initial Surveys for the All of Us Research Program. <i>Epidemiology</i> , 2019 , 30, 597-608	3.1	12
342	Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients. <i>Quality of Life Research</i> , 2019 , 28, 815-827	3.7	29
341	The TBI-CareQOL Measurement System: Development and Preliminary Validation of Health-Related Quality of Life Measures for Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury. <i>Archives of Physical Medicine and Rehabilitation</i> , 2019 , 100, S1-S12	2.8	28
340	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 297-310	21.7	122
339	Understanding Health-Related Quality of Life of Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury: Establishing the Reliability and Validity of PROMIS Social Health Measures. <i>Archives of Physical Medicine and Rehabilitation</i> , 2019 , 100, S110-S118	2.8	19
338	Measurement framework for the Environmental influences on Child Health Outcomes research program. <i>Current Opinion in Pediatrics</i> , 2018 , 30, 276-284	3.2	12
337	Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. <i>Journal of Neurology</i> , 2018 , 265, 1443-1453	5.5	3
336	Conceptual Underpinnings of the Quality of Life in Neurological Disorders (Neuro-QoL): Comparisons of Core Sets for Stroke, Multiple Sclerosis, Spinal Cord Injury, and Traumatic Brain Injury. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018 , 99, 1763-1775	2.8	3
335	Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence. <i>Neurourology and Urodynamics</i> , 2018 , 37, 2586-2596	2.3	10
334	Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. <i>Supportive Care in Cancer</i> , 2018 , 26, 1889-1895	3.9	4
333	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018 , 36, 225-238	4.4	45
332	Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. <i>Annals of Oncology</i> , 2018 , 29, 392-397	10.3	17
331	Development of National Research and Clinical Agendas for Patient-Reported Outcomes in IR: Proceedings from a Multidisciplinary Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2018 , 29, 1-8	2.4	7

330	PROMIS-29 v2.0 profile physical and mental health summary scores. <i>Quality of Life Research</i> , 2018 , 27, 1885-1891	3.7	130
329	Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. <i>Quality of Life Research</i> , 2018 , 27, 1589-1597	3.7	0
328	Feasibility of Collecting Patient-Reported Outcomes for Inpatient Rehabilitation Quality Reporting. <i>Health Services Research</i> , 2018 , 53, 1834-1850	3.4	2
327	Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). <i>Cancer</i> , 2018 , 124, 153-160	6.4	15
326	Response to "Shifting the conversation on outcomes reporting". <i>American Journal of Transplantation</i> , 2018 , 18, 2368-2369	8.7	2
325	Development and validation of the patient roles and responsibilities scale in cancer patients. <i>Quality of Life Research</i> , 2018 , 27, 2923-2934	3.7	6
324	Patient-reported outcomes with nivolumab in advanced solid cancers. <i>Cancer Treatment Reviews</i> , 2018 , 70, 75-87	14.4	11
323	Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 111	3	13
322	Cross-sectional validation of the PROMIS-Preference scoring system. <i>PLoS ONE</i> , 2018 , 13, e0201093	3.7	25
321	Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence. <i>Journal of Urology</i> , 2018 , 200, 848-855	2.5	18
320	Evaluation of options for presenting health-states from PROMIS item banks for valuation exercises. <i>Quality of Life Research</i> , 2018 , 27, 1835-1843	3.7	11
319	Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2018 , 21, 1413-1418	3.3	5
318	Initial Development and Content Validation of a Health-Related Symptom Index for Persons either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions. <i>Value in Health</i> , 2018 , 21, 984-992	3.3	2
317	Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. <i>NeuroImage: Clinical</i> , 2018 , 20, 110-118	5.3	33
316	Symptom Based Clustering of Women in the LURN Observational Cohort Study. <i>Journal of Urology</i> , 2018 , 200, 1323-1331	2.5	7
315	Lessons From the Testosterone Trials. <i>Endocrine Reviews</i> , 2018 , 39, 369-386	27.2	102
314	Cancer symptom response as an oncology clinical trial end point. <i>Expert Review of Quality of Life in Cancer Care</i> , 2018 , 3, 35-46		6
313	Patient-reported outcomes and quality of life measures in atopic dermatitis. <i>Clinics in Dermatology</i> , 2018 , 36, 616-630	3	15

312	Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study. <i>Ecological Management and Restoration</i> , 2018 , 31,	3	8
311	Refining and supplementing candidate measures of psychological well-being for the NIH PROMIS : qualitative results from a mixed cancer sample. <i>Quality of Life Research</i> , 2018 , 27, 2471-2476	3.7	4
310	Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3073-3073	2.2	1
309	Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18743-e18743	2.2	1
308	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS710-TPS710	2.2	1
307	Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 669-669	2.2	
306	Improvement of carcinoid syndrome (CS) symptoms and quality of life (QoL) in CS patients treated with somatostatin analogs (SSAs): Results from longitudinal patient surveys.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 400-400	2.2	
305	Quality of life (QoL) in a phase III trial of pelvic external beam radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk, early stage endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group	2.2	
304	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4597-TPS4597	2.2	
303	Financial toxicity among patients with lung cancer in a publicly funded health care system.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 192-192	2.2	0
302	Patient-Reported Outcomes Validation of the FACT-Leu in Acute Myeloid Leukemia: A Review of Baseline Characteristics in AML2002. <i>Blood</i> , 2018 , 132, 3590-3590	2.2	
301	Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures. <i>Psychological Assessment</i> , 2018 , 30, 450-458	5.3	5
300	Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures. <i>Quality of Life Research</i> , 2018 , 27, 811-822	3.7	8
299	Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. <i>Cancer</i> , 2018 , 124, 991-997	6.4	29
298	Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study. <i>Journal of Urology</i> , 2018 , 199, 528-535	2.5	11
297	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 757-764	2.2	33
296	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1088-1095	2.2	45
295	Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2483-2491	2.2	14

294	Questionnaires measuring quality of life and satisfaction of patients and their relatives in a palliative care setting-German translation of FAMCARE-2 and the palliative care subscale of FACIT-Pal. <i>Annals of Palliative Medicine</i> , 2018 , 7, 420-426	1.7	11
293	Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. <i>Medicine (United States)</i> , 2018 , 97, e13390	1.8	3
292	Depressive symptom prevalence after intracerebral hemorrhage: a multi-center study. <i>Journal of Patient-Reported Outcomes</i> , 2018 , 2, 55	2.6	2
291	Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	16
290	Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. <i>Clinical Therapeutics</i> , 2018 , 40, 2006-2020.e2	3.5	18
289	Comparing how anxiety is experienced between white and minority patients after local therapy for prostate cancer: A hypothesis-generating pilot study. <i>Canadian Urological Association Journal</i> , 2018 ,	1.2	
288	Simplified Chinese translation of 13 adult item banks from the Quality of Life in Neurological Disorders (Neuro-QoL). <i>BMC Health Services Research</i> , 2018 , 18, 825	2.9	2
287	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 879-890	18.1	40
286	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1404-1416	21.7	75
285	Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. <i>Annals of Hematology</i> , 2018 , 97, 2455-2463	3	11
284	A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 759-769	7.1	27
283	Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018 , 150, 119-126	4.9	8
282	Using PROMIS Pain Interference Items to Improve Quality Measurement in Inpatient Rehabilitation Facilities. <i>Journal of the American Medical Directors Association</i> , 2018 , 19, 846-851.e2	5.9	4
281	General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. <i>Value in Health</i> , 2018 , 21, 1313-1321	3.3	36
280	Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS-Preference (PROPr) Scoring System. <i>Medical Decision Making</i> , 2018 , 38, 683-698	2.5	41
279	Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. <i>Journal of Sexual Medicine</i> , 2018 , 15, 997-1009	1.1	9
278	Long-term fear of recurrence in young breast cancer survivors and partners. <i>Psycho-Oncology</i> , 2017 , 26, 22-28	3.9	50
277	Avoidant coping and self-efficacy mediate relationships between perceived social constraints and symptoms among long-term breast cancer survivors. <i>Psycho-Oncology</i> , 2017 , 26, 982-990	3.9	22

276	Coping strategies tailored to the management of fear of recurrence and adaptation for E-health delivery: The FoRtitude intervention. <i>Cancer</i> , 2017 , 123, 906-910	6.4	16
275	Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 717-724	27.4	134
274	Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial. <i>JAMA Internal Medicine</i> , 2017 , 177, 480-490	11.5	120
273	The Dutch-Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain. <i>Journal of Clinical Epidemiology</i> , 2017 , 87, 47-58	5.7	23
272	Parent-reported cognitive function is associated with leukoencephalopathy in children with brain tumors. <i>Quality of Life Research</i> , 2017 , 26, 2541-2550	3.7	7
271	Montreal Accord on Patient-Reported Outcomes (PROs) use series - Paper 6: creating national initiatives to support development and use-the PROMIS example. <i>Journal of Clinical Epidemiology</i> , 2017 , 89, 148-153	5.7	15
270	The Validity and Reliability of the Korean Version of the Stigma Scale for Chronic Illness 8-Items (SSCI-8) in Patients with Neurological Disorders. <i>International Journal of Behavioral Medicine</i> , 2017 , 24, 288-293	2.6	4
269	Scale Linking to Enable Patient-Reported Outcome Performance Measures Assessed with Different Patient-Reported Outcome Measures. <i>Value in Health</i> , 2017 , 20, 1143-1149	3.3	7
268	Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures. <i>Movement Disorders</i> , 2017 , 32, 1096-1102	7	7
267	Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. <i>NeuroImage: Clinical</i> , 2017 , 14, 685-691	5.3	26
266	Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment. <i>Pediatric Dermatology</i> , 2017 , 34, 78-83	1.9	8
265	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. <i>European Journal of Cancer</i> , 2017 , 87, 21-29	7.5	20
264	Two-item PROMIS global physical and mental health scales. <i>Journal of Patient-Reported Outcomes</i> , 2017 , 1, 2	2.6	56
263	Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. <i>Kidney Cancer</i> , 2017 , 1, 31-40	0.6	6
262	Association of fatigue and depression with circulating levels of proinflammatory cytokines and epidermal growth factor receptor ligands: a correlative study of a placebo-controlled fatigue trial. <i>Cancer Management and Research</i> , 2017 , 9, 1-10	3.6	11
261	A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy. <i>Annals of Palliative Medicine</i> , 2017 , 6, S223-S232	1.7	10
260	Computerized Adaptive Testing in Pediatric Brain Tumor Clinics. <i>Journal of Pain and Symptom Management</i> , 2017 , 54, 289-297	4.8	7
259	Selection of key health domains from PROMIS for a generic preference-based scoring system. <i>Quality of Life Research</i> , 2017 , 26, 3377-3385	3.7	26

258	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1411-1422	21.7	49
257	Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials. <i>Neurotherapeutics</i> , 2017 , 14, 934-944	6.4	31
256	Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. <i>Gynecologic Oncology</i> , 2017 , 147, 98-103	4.9	19
255	Linking of the quality of life in neurological disorders (Neuro-QoL) to the international classification of functioning, disability and health. <i>Quality of Life Research</i> , 2017 , 26, 2435-2448	3.7	9
254	Reliability and Validity of the HD-PRO-Triad™, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease. <i>Journal of Huntington Disease</i> , 2017 , 6, 201-215	1.9	1
253	Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities. <i>Clinical Rheumatology</i> , 2017 , 36, 1729-1736	3.9	22
252	Responsiveness of 8 Patient-Reported Outcomes Measurement Information System (PROMIS) measures in a large, community-based cancer study cohort. <i>Cancer</i> , 2017 , 123, 327-335	6.4	43
251	Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COMprehensive Score for financial Toxicity (COST). <i>Cancer</i> , 2017 , 123, 476-484	6.4	281
250	The challenge of measuring intra-individual change in fatigue during cancer treatment. <i>Quality of Life Research</i> , 2017 , 26, 259-271	3.7	6
249	Agitation, Delirium, and Cognitive Outcomes in Intracerebral Hemorrhage. <i>Psychosomatics</i> , 2017 , 58, 19-27	2.6	22
248	The Comparability of Functional Assessment of Chronic Illness Therapy - Fatigue Scores between Cancer and Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 57-63	2.3	1
247	The impact of sleep disturbances (SD) on quality of life, psychological morbidity, and survival of advanced cancer patients (ACP) and caregivers (CG).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10115-10115 ^{2,2}	2.2	1
246	Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6074-6074	2.2	3
245	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4596-TPS4596	2.2	7
244	Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 155-155 ^{2,2}	2.2	7
243	Association between duration of somatostatin analogs (SSAs) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15693-e15693	2.2	7
242	Multimodal therapy for cancer related fatigue in patients with prostate cancer receiving radiotherapy and androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10114-10114	2.2	1
241	Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 830-41	5	45

240	Dutch-Flemish translation of nine pediatric item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS) . <i>Quality of Life Research</i> , 2016 , 25, 761-5	3.7	22
239	SAT0620 Validation of The Dutch-Flemish Promis Fatigue Item Bank in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 894.2-894	2.4	
238	Research letter: Impact of pruritus on quality of life-A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 885-886.e4	4.5	19
237	HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). <i>Quality of Life Research</i> , 2016 , 25, 2441-2455	3.7	34
236	Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2016 , 122, 287-95	6.4	11
235	Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls. <i>Cancer</i> , 2016 , 122, 258-68	6.4	22
234	Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. <i>Supportive Care in Cancer</i> , 2016 , 24, 3661-8	3.9	30
233	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 994-1003	21.7	161
232	Health-related quality of life among women with ductal carcinoma in situ or early invasive breast cancer: validation of the FACT-B (version 4). <i>Expert Review of Quality of Life in Cancer Care</i> , 2016 , 1, 99-109		10
231	The PROMIS satisfaction with social participation measures demonstrated responsiveness in diverse clinical populations. <i>Journal of Clinical Epidemiology</i> , 2016 , 73, 135-41	5.7	51
230	Comparison of interactive voice response (IVR) with paper administration of instruments to assess functional status, sexual function, and quality of life in elderly men. <i>Quality of Life Research</i> , 2016 , 25, 811-21	3.7	5
229	Overview of the obesity intervention taxonomy and pooled analysis working group. <i>Translational Behavioral Medicine</i> , 2016 , 6, 244-59	3.2	7
228	Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format. <i>Quality of Life Research</i> , 2016 , 25, 637-49	3.7	40
227	A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 77-84	4.4	10
226	Pazopanib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 61-9	3.2	20
225	Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. <i>Lung</i> , 2016 , 194, 227-34	2.9	65
224	Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples. <i>Journal of Clinical Epidemiology</i> , 2016 , 73, 119-27	5.7	189
223	PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions. <i>Journal of Clinical Epidemiology</i> , 2016 , 73, 89-102	5.7	224

222	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 2008-16	4 ⁰	374
221	PROMIS Fatigue Item Bank had Clinical Validity across Diverse Chronic Conditions. <i>Journal of Clinical Epidemiology</i> , 2016 , 73, 128-34	5.7	104
220	Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior. <i>Journal of Clinical Epidemiology</i> , 2016 , 73, 103-11	5.7	86
219	Evaluating Individual Change With the Quality of Life in Neurological Disorders (Neuro-QoL) Short Forms. <i>Archives of Physical Medicine and Rehabilitation</i> , 2016 , 97, 650-654.e8	2.8	24
218	Dose Escalation in Stage III Non-Small-Cell Lung Cancer: Patients Agree With the Clinical Results. <i>JAMA Oncology</i> , 2016 , 2, 368-9	13.4	
217	Quality of life (QOL) analysis from CHARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5004-5004	2.2	2
216	Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. <i>Journal of Community and Supportive Oncology</i> , 2016 , 14, 148-54		7
215	Measurement Equivalence of the Patient Reported Outcomes Measurement Information System (PROMIS) Applied Cognition - General Concerns, Short Forms in Ethnically Diverse Groups 2016 , 58, 255-307		16
214	Measuring social function in diverse cancer populations: Evaluation of measurement equivalence of the Patient Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities short form 2016 , 58, 403-421		5
213	Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer. <i>Annals of Palliative Medicine</i> , 2016 , 5, 13-21	1.7	6
212	Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4549-4549	2.2	1
211	Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5060-5060	2.2	
210	Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 593-593	2.2	
209	Death anxiety, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10073-10073	2.2	
208	Quality of life with Brain Symptom and Impact Questionnaire in patients with brain metastases. <i>Annals of Palliative Medicine</i> , 2016 , 5, 179-89	1.7	1
207	Calibration of the Dutch-Flemish PROMIS Pain Behavior item bank in patients with chronic pain. <i>European Journal of Pain</i> , 2016 , 20, 284-96	3.7	17
206	Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 725-33	7	27
205	New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). <i>Quality of Life Research</i> , 2016 , 25, 2403-2415	3.7	23

204	Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. <i>Cancer</i> , 2016 , 122, 1108-15	6.4	29
203	Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. <i>Supportive Care in Cancer</i> , 2016 , 24, 3695-703	3.9	46
202	A PROMIS Measure of Neuropathic Pain Quality. <i>Value in Health</i> , 2016 , 19, 623-30	3.3	20
201	Validity of PROMIS physical function measured in diverse clinical samples. <i>Journal of Clinical Epidemiology</i> , 2016 , 73, 112-8	5.7	112
200	Patient and health care provider perceptions of cancer-related fatigue and pain. <i>Supportive Care in Cancer</i> , 2016 , 24, 4357-63	3.9	34
199	The Brain Symptom and Impact Questionnaire in brain metastases patients: a prospective long-term follow-up study. <i>CNS Oncology</i> , 2016 , 5, 31-40	4	4
198	Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. <i>Clinical Therapeutics</i> , 2016 , 38, 769-773	3.5	25
197	Using Linear Equating to Map PROMIS () Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark. <i>Pharmacoeconomics</i> , 2016 , 34, 1015-22	4.4	33
196	Itch in the General Internal Medicine Setting: A Cross-Sectional Study of Prevalence and Quality-of-Life Effects. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 681-690	7.1	22
195	Do patients with brain metastases selected for whole brain radiotherapy have worse baseline quality of life as compared to those for radiosurgery or neurosurgery (with or without whole brain radiotherapy)?. <i>Annals of Palliative Medicine</i> , 2016 , 5, 1-12	1.7	4
194	Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015 , 33, 740-8	2.2	30
193	Health-related quality of life measurement in oncology: advances and opportunities. <i>American Psychologist</i> , 2015 , 70, 175-85	9.5	32
192	Validation of the Neuro-QoL measurement system in children with epilepsy. <i>Epilepsy and Behavior</i> , 2015 , 46, 209-14	3.2	14
191	Bringing PROMIS to practice: brief and precise symptom screening in ambulatory cancer care. <i>Cancer</i> , 2015 , 121, 927-34	6.4	139
190	Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis. <i>Journal of Rheumatology</i> , 2015 , 42, 64-72	4.1	31
189	Spanish translation and linguistic validation of the quality of life in neurological disorders (Neuro-QoL) measurement system. <i>Quality of Life Research</i> , 2015 , 24, 753-6	3.7	8
188	Bevacizumab and quality of life in advanced cervical cancer. <i>Lancet Oncology</i> , 2015 , 16, 241-3	21.7	6
187	Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. <i>Annals of Oncology</i> , 2015 , 26, 179-185	10.3	50

186	U.S. General Population Estimate for "Excellent" to "Poor" Self-Rated Health Item. <i>Journal of General Internal Medicine</i> , 2015 , 30, 1511-6	4	74
185	Linking Physical and Mental Health Summary Scores from the Veterans RAND 12-Item Health Survey (VR-12) to the PROMIS() Global Health Scale. <i>Journal of General Internal Medicine</i> , 2015 , 30, 1524-30	4	51
184	Establishing a common metric for self-reported pain: linking BPI Pain Interference and SF-36 Bodily Pain Subscale scores to the PROMIS Pain Interference metric. <i>Quality of Life Research</i> , 2015 , 24, 2305-18	3.7	37
183	Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. <i>Quality of Life Research</i> , 2015 , 24, 2333-44	3.7	107
182	Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS() Physical Function. <i>Journal of General Internal Medicine</i> , 2015 , 30, 1517-23	4	44
181	Testing the PROMIS() Depression measures for monitoring depression in a clinical sample outside the US. <i>Journal of Psychiatric Research</i> , 2015 , 68, 140-50	5.2	24
180	Quality of life in patients with TIA and minor ischemic stroke. <i>Neurology</i> , 2015 , 85, 1957-63	6.5	46
179	Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. <i>Surgery</i> , 2015 , 158, 837-45	3.6	27
178	Agreement Between Responses From Community-Dwelling Persons With Stroke and Their Proxies on the NIH Neurological Quality of Life (Neuro-QoL) Short Forms. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015 , 96, 1986-92.e14	2.8	27
177	Recruitment and Screening for the Testosterone Trials. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015 , 70, 1105-11	6.4	23
176	The impact of events scale: a comparison of frequency versus severity approaches to measuring cancer-specific distress. <i>Psycho-Oncology</i> , 2015 , 24, 1738-45	3.9	21
175	THU0599 Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 418.1-418	2.4	
174	Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia. <i>Patient Related Outcome Measures</i> , 2015 , 6, 205-14	2.9	4
173	Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic Pain. <i>PLoS ONE</i> , 2015 , 10, e0134094	3.7	25
172	Patient-reported outcomes as end points and outcome indicators in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 358-70	19.4	46
171	Reference values of the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being: a report from the American Cancer Society's studies of cancer survivors. <i>Cancer</i> , 2015 , 121, 1838-44	6.4	51
170	Development and validation of the functional assessment of cancer therapy-angiogenesis subscale. <i>Cancer Medicine</i> , 2015 , 4, 690-8	4.8	9
169	Quality of life associated factors in head and neck cancer patients in a developing country using the FACT-H&N. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2015 , 43, 274-80	3.6	16

168	Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18). <i>Gynecologic Oncology</i> , 2015 , 136, 317-22	4.9	9
167	Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers. <i>Quality of Life Research</i> , 2015 , 24, 575-89	3.7	47
166	Development and Validation of a Quality-of-Life Instrument for Infantile Hemangiomas. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 1533-1539	4.3	20
165	Grading financial toxicity based upon its impact on health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6618-6618	2.2	2
164	Validation of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17753-e17753	2.2	7
163	Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 403-403	2.2	17
162	Implementation of distress screening in an oncology setting. <i>Journal of Community and Supportive Oncology</i> , 2015 , 13, 423-8		11
161	The relationship between health utility, quality of life, and symptom scores in Canadian patients with esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 149-149	2.2	
160	Hippocampal memory impairment in breast cancer survivors after chemotherapy measurement using covert testing.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1024-1024	2.2	1
159	Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6607-6607	2.2	0
158	Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. <i>Cancer</i> , 2014 , 120, 2902-9	6.4	47
157	Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3948-58	2.2	89
156	Patient-Reported Outcomes Measurement Information System (PROMIS): efficient, standardized tools to measure self-reported health and quality of life. <i>Nursing Outlook</i> , 2014 , 62, 339-45	2.7	104
155	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , 2014 , 15, 1147-56	21.7	154
154	Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. <i>Quality of Life Research</i> , 2014 , 23, 2651-61	3.7	95
153	Establishing a common metric for self-reported anxiety: linking the MASQ, PANAS, and GAD-7 to PROMIS Anxiety. <i>Journal of Anxiety Disorders</i> , 2014 , 28, 88-96	10.9	146
152	Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy. <i>Epilepsy and Behavior</i> , 2014 , 31, 77-84	3.2	29
151	THU0563 Validation of the Dutch-Flemish PROMIS Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 377.2-377	2.4	

150	THU0564 Validation of the Dutch-Flemish PROMIS Physical Functioning Item Bank in Patients with Chronic Pain. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 377.3-378	2.4	
149	New English and Spanish social health measures will facilitate evaluating health determinants. <i>Health Psychology</i> , 2014 , 33, 490-9	5	151
148	The comparability of English, French and Dutch scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): an assessment of differential item functioning in patients with systemic sclerosis. <i>PLoS ONE</i> , 2014 , 9, e91979	3.7	10
147	The impact of symptom burden on patient quality of life in chronic myeloid leukemia. <i>Oncology</i> , 2014 , 87, 133-47	3.6	16
146	Establishing a common metric for depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS depression. <i>Psychological Assessment</i> , 2014 , 26, 513-27	5.3	267
145	Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	165
144	Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014 , 120, 1871-80	6.4	14
143	Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. <i>Cancer Medicine</i> , 2014 , 3, 1353-8	4.8	7
142	The development of a financial toxicity patient-reported outcome in cancer: The COST measure. <i>Cancer</i> , 2014 , 120, 3245-53	6.4	235
141	US valuation of health outcomes measured using the PROMIS-29. <i>Value in Health</i> , 2014 , 17, 846-53	3.3	76
140	Self-reported cognitive concerns and abilities: two sides of one coin?. <i>Psycho-Oncology</i> , 2014 , 23, 1133-41	3.9	74
139	Reply to S. Barni et Al and M. Sun et Al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3783-4	2.2	0
138	Current Challenges in Using Patient-Reported Outcomes for Surgical Care and Performance Measurement: Everybody Wants to Hear From the Patient, but Are We Ready to Listen?. <i>JAMA Surgery</i> , 2014 , 149, 505-6	5.4	41
137	Linking fatigue measures on a common reporting metric. <i>Journal of Pain and Symptom Management</i> , 2014 , 48, 639-48	4.8	28
136	Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 26.e25-31	2.8	1
135	Content validation of the FACT-Br with patients and health-care professionals to assess quality of life in patients with brain metastases. <i>Journal of Radiation Oncology</i> , 2014 , 3, 105-113	0.7	5
134	Prospective longitudinal evaluation of a symptom cluster in breast cancer. <i>Journal of Pain and Symptom Management</i> , 2014 , 47, 721-30	4.8	50
133	Parent-reported cognition of children with cancer and its potential clinical usefulness. <i>Quality of Life Research</i> , 2014 , 23, 1049-58	3.7	32

132	Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4581-4581	2.2	2
131	Relative influence of factors determining a woman's preference for treatment options in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5544-5544	2.2	2
130	Comparing cancer patient and provider perspectives on fatigue and pain.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17680-e17680	2.2	1
129	A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 155-155	2.2	1
128	A history of health-related quality of life outcomes in psychiatry. <i>Dialogues in Clinical Neuroscience</i> , 2014 , 16, 127-35	5.7	49
127	Marital distress (MD), quality of life, and psychological morbidity among advanced cancer patients (ACP) in phase I trials and their spousal caregivers (SC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9578-9578 ^{2.2}	2.2	1
126	Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4601-TPS4601	2.2	1
125	Patient-relevant symptoms and impacts of chronic lymphocytic leukemia: Evidence from online social networks-based qualitative research with treated and watch and wait patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17692-e17692	2.2	
124	Assessment of single screening questions for dysphagia for routine clinical use in a tertiary care practice.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 102-102	2.2	
123	Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 259-259	2.2	
122	Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. <i>Quality of Life Research</i> , 2013 , 22, 1105-12	3.7	35
121	Assessment of self-reported negative affect in the NIH Toolbox. <i>Psychiatry Research</i> , 2013 , 206, 88-97	9.9	37
120	The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. <i>Gynecologic Oncology</i> , 2013 , 128, 187-90	4.9	16
119	Evaluation of treatment- and disease-related symptoms in advanced head and neck cancer: validation of the national comprehensive cancer network-functional assessment of cancer therapy-head and neck cancer symptom index-22 (NFHNSI-22). <i>Journal of Pain and Symptom Management</i> , 2013 , 46, 113-20	4.8	6
118	Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. <i>Journal of Bone Oncology</i> , 2013 , 2, 154-7	4.5	12
117	Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. <i>British Journal of Cancer</i> , 2013 , 108, 1571-8	8.7	52
116	The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. <i>Annals of Oncology</i> , 2013 , 24, 1073-8	10.3	60
115	Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 17-17	2.2	2

114	Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 346-346	2.2	4
113	Quality of Life in Patients with Advanced Cancer Using the Functional Assessment of Cancer Therapy-General Assessment Tool: A Literature Review. <i>World Journal of Oncology</i> , 2013 , 4, 8-17	16.7	3
112	Validation of the supplementary quality of life questionnaire for mouth/throat and hand/foot soreness.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9574-9574	2.2	
111	Pain and other symptoms in patients with hepatocellular carcinoma (HCC): A qualitative analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15187-e15187	2.2	1
110	Is there an additional health-related quality of life (HRQL) benefit with abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) beyond that mediated by clinical endpoints?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9617-9617	2.2	
109	Development and validation of the functional assessment of cancer therapy: Antiangiogenesis (FACT-AntiA).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20527-e20527	2.2	
108	Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. <i>European Journal of Cancer</i> , 2012 , 48, 311-23	7.5	36
107	Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire. <i>Value in Health</i> , 2012 , 15, 1051-8	3.3	79
106	Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. <i>Neurology</i> , 2012 , 78, 1860-7	6.5	360
105	Quality-of-life measures in children with neurological conditions: pediatric Neuro-QOL. <i>Neurorehabilitation and Neural Repair</i> , 2012 , 26, 36-47	4.7	52
104	Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2012 , 106, 646-50	8.7	21
103	Quality of Life in Patients With Primary and Metastatic Brain Tumors in the Literature as Assessed by the FACT-Br. <i>World Journal of Oncology</i> , 2012 , 3, 280-285	16.7	1
102	Patients' and Health Care Providers' Evaluation of Quality of Life Issues in Advanced Cancer Using Functional Assessment of Chronic Illness Therapy - Palliative Care Module (FACIT-Pal) Scale. <i>World Journal of Oncology</i> , 2012 , 3, 210-216	16.7	1
101	Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012 , 120, 235-235	2.2	
100	How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. <i>Archives of Physical Medicine and Rehabilitation</i> , 2011 , 92, S20-7	2.8	188
99	The neurology quality-of-life measurement initiative. <i>Archives of Physical Medicine and Rehabilitation</i> , 2011 , 92, S28-36	2.8	132
98	Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 507-16	5.7	384
97	Spiritual Well-Being as a Component of Health-Related Quality of Life: The Functional Assessment of Chronic Illness TherapySpiritual Well-Being Scale (FACIT-Sp). <i>Religions</i> , 2011 , 2, 77-94	0.6	142

96	Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 268-78	7.3	32
95	A new index of priority symptoms in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2011 , 120, 214-9	4.9	35
94	The impact of missing data on estimation of health-related quality of life outcomes: an analysis of a randomized longitudinal clinical trial. <i>Health Services and Outcomes Research Methodology</i> , 2011 , 11, 134-144	1.6	2
93	Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy--Fatigue (FACIT-F) questionnaire. <i>Supportive Care in Cancer</i> , 2011 , 19, 1441-50	3.9	61
92	Parent-perceived child cognitive function: results from a sample drawn from the US general population. <i>Childs Nervous System</i> , 2011 , 27, 285-93	1.7	17
91	Development of a parent-report cognitive function item bank using item response theory and exploration of its clinical utility in computerized adaptive testing. <i>Journal of Pediatric Psychology</i> , 2011 , 36, 766-79	3.2	35
90	Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. <i>Oncologist</i> , 2011 , 16 Suppl 2, 23-31	5.7	35
89	Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS [®]): depression, anxiety, and anger. <i>Assessment</i> , 2011 , 18, 263-83	3.7	980
88	Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?. <i>Blood</i> , 2011 , 118, 1025-1025	2.2	1
87	Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05. <i>Blood</i> , 2011 , 118, 4184-4184	2.2	3
86	Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. <i>British Journal of Cancer</i> , 2010 , 102, 658-64	8.7	45
85	Building a measure of fatigue: the functional assessment of Chronic Illness Therapy Fatigue Scale. <i>PM and R</i> , 2010 , 2, 359-63	2.2	41
84	Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 1169-78	5.7	301
83	The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 1179-94	5.7	2437
82	Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 1195-204	5.7	246
81	Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. <i>HIV Clinical Trials</i> , 2010 , 11, 18-27		13
80	Measuring Social Well-Being in People with Chronic Illness. <i>Social Indicators Research</i> , 2010 , 96, 381-401	2.7	29
79	Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. <i>Quality of Life Research</i> , 2010 , 19, 125-36	3.7	173

78	Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. <i>Quality of Life Research</i> , 2010 , 19, 1035-44	3.7	183
77	Patient-reported outcomes measurement information system (PROMIS) domain names and definitions revisions: further evaluation of content validity in IRT-derived item banks. <i>Quality of Life Research</i> , 2010 , 19, 1311-21	3.7	127
76	Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2010 , 119, 531-7	4.9	29
75	Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. <i>Gynecologic Oncology</i> , 2010 , 119, 538-42	4.9	27
74	The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. <i>Journal of Applied Measurement</i> , 2010 , 11, 304-14	0.3	152
73	Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial. <i>Blood</i> , 2010 , 116, 3826-3826	2.2	
72	Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. <i>Journal of Oncology Practice</i> , 2009 , 5, 66-70	3.1	26
71	Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. <i>Journal of Rheumatology</i> , 2009 , 36, 2061-6	4.1	184
70	A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009 , 112, 543-52	4.9	160
69	Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. <i>Quality of Life Research</i> , 2009 , 18, 873-80	3.7	824
68	Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. <i>Value in Health</i> , 2009 , 12, 124-9	3.3	131
67	Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. <i>Cancer Treatment Reviews</i> , 2009 , 35, 733-7	14.4	28
66	Classical test theory and item response theory/Rasch model to assess differences between patient-reported fatigue using 7-day and 4-week recall periods. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 991-7	5.7	25
65	Disease Burden and Treatment Impact Associated with Myelodysplastic Syndromes: Preliminary Findings From a Web-Based Survey.. <i>Blood</i> , 2009 , 114, 4522-4522	2.2	
64	Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. <i>Clinical Lung Cancer</i> , 2008 , 9, 51-8	4.9	13
63	Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3763-9	2.2	103
62	Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2008 , 107, 167-80	4.4	185
61	Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 515-26	4.4	52

60	Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization. <i>Quality of Life Research</i> , 2008 , 17, 1137-46	3.7	85
59	Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. <i>Cancer</i> , 2008 , 113, 1480-8	6.4	15
58	Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. <i>Health and Quality of Life Outcomes</i> , 2007 , 5, 70	3	512
57	A comparison of three sets of criteria for determining the presence of differential item functioning using ordinal logistic regression. <i>Quality of Life Research</i> , 2007 , 16 Suppl 1, 69-84	3.7	104
56	The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. <i>Quality of Life Research</i> , 2007 , 16 Suppl 1, 133-41	3.7	410
55	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. <i>Quality of Life Research</i> , 2007 , 16, 1615-26	3.7	17
54	The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. <i>Medical Care</i> , 2007 , 45, S3-S11	3.1	1660
53	Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2007 , 53-60	4.8	19
52	Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Medical Care</i> , 2007 , 45, S22-31	3.1	1001
51	Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5106-12	2.2	310
50	Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?. <i>European Urology</i> , 2006 , 49, 781-9	10.2	17
49	Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. <i>European Journal of Cancer</i> , 2006 , 42, 3169-77	7.5	57
48	Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. <i>Quality of Life Research</i> , 2006 , 15, 1179-90	3.7	93
47	Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 273-84	4.4	191
46	Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy--thrombocytopenia (FACT-Th) questionnaire. <i>Supportive Care in Cancer</i> , 2006 , 14, 1220-31	3.9	18
45	Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5007-5007	2.2	5
44	The Patient's Experience of Fatigue: A Cross-Sectional Study of Cancer Patients.. <i>Blood</i> , 2006 , 108, 3356-3356		
43	Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). <i>The Journal of Supportive Oncology</i> , 2006 , 4, 191-9		63

42	The FDA and the person with cancer: give PROs a chance. <i>Oncology</i> , 2006 , 20, 436	1.8	2
41	Quality of life and clinical decisions in chemotherapy-induced anemia. <i>Oncology</i> , 2006 , 20, 25-8	1.8	8
40	Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment Of Cancer Therapy-Lung scale. <i>Hematology/Oncology Clinics of North America</i> , 2005 , 19, 389-420, viii	3.1	35
39	A comprehensive method for the translation and cross-cultural validation of health status questionnaires. <i>Evaluation and the Health Professions</i> , 2005 , 28, 212-32	2.5	361
38	Defining higher order dimensions of self-reported health: further evidence for a two-dimensional structure. <i>Evaluation and the Health Professions</i> , 2005 , 28, 122-41	2.5	15
37	Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2946-54	2.2	97
36	Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 811-9	4.1	283
35	The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. <i>Clinical and Experimental Rheumatology</i> , 2005 , 23, S53-7	2.2	240
34	The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. <i>Annals of Oncology</i> , 2004 , 15, 979-86	10.3	169
33	The Functional Assessment of Cancer Therapy-Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. <i>Seminars in Oncology</i> , 2004 , 31, 11-5	5.5	69
32	Quality of life considerations in patients with advanced lung cancer. <i>Seminars in Oncology</i> , 2004 , 31, 16-20	5	95
31	The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. <i>Quality of Life Research</i> , 2004 , 13, 137-54	3.7	36
30	Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2159-66	3.2	453
29	A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. <i>Journal of Clinical Epidemiology</i> , 2004 , 57, 898-910	5.7	270
28	Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. <i>Annals of Oncology</i> , 2003 , 14, 511-9	10.3	82
27	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. <i>Cancer</i> , 2003 , 98, 406-12	6.4	47
26	Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). <i>Cancer</i> , 2003 , 98, 822-31	6.4	205
25	What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). <i>Cancer Investigation</i> , 2003 , 21, 526-35	2.1	81

24	Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. <i>Journal of Clinical Oncology</i> , 2003 , 21, 366-73 ^{2,2}	23.2	170
23	Fatigue in cancer patients compared with fatigue in the general United States population. <i>Cancer</i> , 2002 , 94, 528-38	6.4	520
22	Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. <i>Quality of Life Research</i> , 2002 , 11, 207-21	3.7	374
21	Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). <i>Annals of Behavioral Medicine</i> , 2002 , 24, 49-58	4.5	1078
20	Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. <i>Archives of Physical Medicine and Rehabilitation</i> , 2002 , 83, S10-7	2.8	164
19	What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. <i>Journal of Clinical Epidemiology</i> , 2002 , 55, 285-95	5.7	299
18	Advances in quality of life measurements in oncology patients. <i>Seminars in Oncology</i> , 2002 , 29, 60-8	5.5	57
17	The effects of anemia and anemia treatment on the quality of life of people with cancer. <i>Oncology</i> , 2002 , 16, 125-32	1.8	23
16	A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. <i>Health Psychology</i> , 2002 , 21, 564-72	5	121
15	Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2114-22	2.2	234
14	Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. <i>Journal of Clinical Oncology</i> , 2000 , 18, 623-31	2.2	497
13	Assessment methods for quality of life in cancer patients: the FACIT measurement system. <i>Pharmaceutical Medicine</i> , 2000 , 14, 78-81		16
12	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 189-99	4.4	242
11	Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). <i>Quality of Life Research</i> , 1999 , 8, 723-31	3.7	43
10	Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. <i>Quality of Life Research</i> , 1999 , 8, 181-95	3.7	305
9	The effect of Epoetin alfa on quality of life in anemic cancer patients. <i>Cancer Practice</i> , 1999 , 7, 177-82		35
8	Age-related differences in the quality of life of breast carcinoma patients after treatment. <i>Cancer</i> , 1999 , 86, 1768-1774	6.4	248
7	Age-related differences in the quality of life of breast carcinoma patients after treatment 1999 , 86, 1768		2

6	Age-related differences in the quality of life of breast carcinoma patients after treatment 1999 , 86, 1768		4
5	A case for including spirituality in quality of life measurement in oncology 1999 , 8, 417		12
4	Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. <i>Statistics in Medicine</i> , 1998 , 17, 547-59	2.3	23
3	Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions 1998 , 17, 547		2
2	Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology60-68		1
1	A short form of the Crisis in Family Systems (CRISYS) in a racially diverse sample of pregnant women. <i>Current Psychology</i> ,1		1.4